Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05024045 · ClinicalTrials.gov registry record · Phase 1

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

A Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkin, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 1
Development phase
316
Enrollment target
20
Study locations

NCT05024045 is a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 316 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05024045, a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
316 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

Conditions Studied

Multiple Myeloma Lymphoma, Non-Hodgkin B-cell Lymphoma Waldenstrom Macroglobulinemia Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Mantle-Cell Lymphoma, B-cell Marginal Zone

Interventions

  • DRUG Pirtobrutinib
  • DRUG LOXO-338

Study Locations (20)

Other

  • CHRU de Montpellier-Hopital St Eloi - Montpellier
  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu - Nantes
  • Institut Curie - Paris
  • Centre hospitalier universitaire de Haut Leveque - Pessac
  • IRCCS - AOU di Bologna - Bologna

California

  • City of Hope National Medical Center - Duarte
  • University of California San Francisco, Medical Center at Paranassus - San Francisco

Florida

  • Mayo Clinic in Florida - Jacksonville
  • Sylvester Comprehensive Cancer Center - Miami

Arizona

  • The University of Arizona Cancer Center - Tucson

Georgia

  • Emory University - Atlanta

Indiana

  • Indiana Blood & Marrow Transplantation (IBMT) - Indianapolis

Kansas

  • University of Kansas Medical Center - Westwood

Massachusetts

  • Tufts Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 316 participants
Start Date 2021-09-30
Est. Completion 2026-06
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05024045

The ClinicalTrials.gov registry entry for NCT05024045 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (42% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Pirtobrutinib is the first listed.

NCT05024045 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05024045 about?

NCT05024045 is a clinical study titled "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers". The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

What is the current status of trial NCT05024045?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 316 participants. The study started on 2021-09-30. Estimated completion is 2026-06.

What conditions does trial NCT05024045 study?

This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell.

What interventions are being tested in trial NCT05024045?

The interventions under investigation include: Pirtobrutinib (DRUG), LOXO-338 (DRUG).

Who is sponsoring clinical trial NCT05024045?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05024045 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Lymphoma, Non-Hodgkin

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.